1. Home
  2. PTLO vs LYEL Comparison

PTLO vs LYEL Comparison

Compare PTLO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$3.78

Market Cap

326.3M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$10.54

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTLO
LYEL
Founded
1963
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
326.3M
320.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
PTLO
LYEL
Price
$3.78
$10.54
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$8.06
$30.60
AVG Volume (30 Days)
1.2M
88.6K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$732,066,000.00
$36,000.00
Revenue This Year
$9.02
N/A
Revenue Next Year
$5.81
$8,712.13
P/E Ratio
$41.78
N/A
Revenue Growth
3.03
N/A
52 Week Low
$3.72
$10.46
52 Week High
$6.83
$45.00

Technical Indicators

Market Signals
Indicator
PTLO
LYEL
Relative Strength Index (RSI) 30.26 27.52
Support Level N/A N/A
Resistance Level $4.86 $15.38
Average True Range (ATR) 0.16 0.77
MACD -0.08 -0.39
Stochastic Oscillator 6.63 2.56

Price Performance

Historical Comparison
PTLO
LYEL

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: